Citations

Clear

6055 citation(s) found for "Vu, Peter".

Defining ideal middle cerebral artery bifurcation aneurysm size for Woven EndoBridge embolization
Adeeb, Nimer , Aslan, Assala , Alla, Anika, McLellan, Rachel , Lay, Sovann V. , Guenego, Adrien , Renieri, Leonardo, Premat, Kévin, Möhlenbruch, Markus, Kral, Michael , Doron, Omer , Salem, Mohamed M. , Foreman, Paul M. , Vachhani, Jay A. , Shaikh, Hamza , Župančić, Vedran , Tutino, Vincent M., Mohammed, Marwa A. , Özateş, Mehmet Özgür , Ayberk, Gıyas , Rabinov, James D. , Ren, Yifan , Michelozzi, Caterina , Elens, Stéphanie , Starke, Robert M, Ogilvie, Mark , Nguyên, Anh , Jones, Jesse , Brinjikji, Waleed , Nawka, Marie Teresa , Psychogios, Marios, Ulfert, Christian , Diestro, Jose Danilo Bengzon , Pukenas, Bryan , Burkhardt, Jan‐Karl , Sheth, Sunil G. , Spiegel, Gary, Lubicz, Boris , Puri, Ajit S , Pero, Guglielmo , Nossek, Erez , Raz, Eytan , Killer-Oberfalzer, Monika, Asadi, Hamed , Brook, Allan , Altschul, David , Ducruet, Andrew F. , Albuquerque, Felipe C. , Regenhardt, Robert W. , Stapleton, Christopher J. , Kan, Peter , Kalousek, Vladimir , Lylyk, Pedro , Boddu, Srikanth , Knopman, Jared , Tjoumakaris, Stavropoula , Clarençon, Frédéric , Cuellar-Saenz, Hugo H., Jabbour, Pascal , Patel, Aman B. , Tutino, Vincent M. , Ibrahim, Mohamed K. , Diestro, Jose Danilo B , Shotar, Eimad , Tutino, Vincent M , Nguyen, Anh , Pero, Guglielmo , Kalousek, Vladimir , Altschul, David J , Regenhardt, Robert W , Ulfert, Christian , Lay, Sovann V , Burkhardt, Jan‐Karl , Musmar, Basel , Salim, Hamza , Cancelliere, Nicole M , Algin, Oktay , Ghozy, Sherief , Dibas, Mahmoud , Renieri, Leonardo , Carnevale, Joseph Anthony , Saliou, Guillaume , Mastorakos, Panagiotis , Naamani, Kareem El , Shotar, Eimad , Premat, Kévin , Möhlenbruch, Markus , Chung, Charlotte , Lylyk, Iván , Hafeez, Muhammad Ubaid , Catapano, Joshua S , Waqas, Muhammad , Schirmer, Clemens M. , Piano, Mariangela , Kühn, Anna Luisa , Hassan, Ameer E , Psychogios, Marios‐Nikos , Domingo, Ricardo A. , Huynh, Thien , Martinez-Gutierrez, Juan Carlos , Essibayi, Muhammed Amir , Sheth, Sunil A., Tawk, Rabih G. , Panni, Pietro , Griessenauer, Christoph J. , Siddiqui, Adnan H. , Aziz‐Sultan, Mohammad Ali , Limbucci, Nicola , Cuellar, Hugo , Jabbour, Pascal , Mendes Pereira, Vitor , Dmytriw, Adam A.

Mayo Clinic

Journal of Neurosurgery | October 12, 2024 | Volume: No volume available | Issue: No issue available | Pages: 1-11

10.3171/2024.5.jns232204 | PMID 39393093 Get It

OBJECTIVE The Woven EndoBridge (WEB) device was approved to treat wide-necked bifurcation aneurysms. The device is designed as an intrasaccular flow disruptor covering aneurysm widths up to 10 mm. Although prior studies combined all aneurysm sizes, it is known that aneurysms behave differently in response to endovascular treatment based on their size. Therefore, the authors’ objective was to identify ideal middle cerebral artery (MCA) aneurysm width and neck sizes most suitable for WEB treatment. METHODS The WorldWideWEB consortium is a large multicenter retrospective database that analyzes intracranial aneurysms treated with the WEB device. In this study, all unruptured MCA bifurcation aneurysms with available measurements were included. Cutoff values based on aneurysm width and neck in relation to aneurysm occlusion status were measured using the receiver operating characteristic (ROC) curve. Propensity score matching (PSM) was then used to compare treatment outcomes between aneurysms smaller and larger than the cutoff value for both width and neck size. RESULTS The ideal cutoff values for MCA bifurcation aneurysm width and neck were 6.1 mm and 4.6 mm, respectively. On PSM, 87 matched pairs were compared based on width size (≤ 6.1 mm and > 6.1 mm), and 77 matched pairs were compared based on neck size (≤ 4.6 mm and > 4.6 mm). There was a significant difference in adequate aneurysm occlusion between aneurysms smaller and larger than those cutoff values for both widths (93% vs 76%, p = 0.0017) and neck sizes (90% vs 70%, p = 0.0026). The retreatment rate was also significantly higher for larger aneurysms in both parameters. CONCLUSIONS This study shows that MCA bifurcation aneurysms ≤ 6.1 mm in width and ≤ 4.6 mm in neck size are significantly better candidates for WEB treatment, leading to improved occlusion status and reduced retreatment rate, which are important considerations when using WEB devices.
Preservation of coagulation function by normothermic machine perfusion in liver transplant as evidenced by thromboelastography parameters
Su, Leon , Secor, Daniel T. , McGary, Alyssa , Nguyen, Michelle , Kinard, Theresa N. , Adamski, Jill , Stoker, Alex D., Frasco, Peter E. , Su, Leon L , McGary, Alyssa K, Nguyen, Michelle C , Jadlowiec, Caroline , Adamksi, Jill , Stoker, Alex D , Jadlowiec, Caroline C. , Williams, Lance A

Mayo Clinic

Liver Transplantation | October 11, 2024 | Volume: 31 | Issue: 4 | Pages: 464-475

10.1097/lvt.0000000000000507 | PMID 39641139 Get It

The use of normothermic machine perfusion (NMP) over static cold storage in liver transplantation has been shown to reduce posttransplant risks of early allograft dysfunction, primary nonfunction, and ischemic cholangiopathy, and its increasing use has played a role in the expanded utilization of marginal livers. While studies have demonstrated improved clinical outcomes using NMP over static cold storage preservation, real-time intraoperative data reflecting the quality and viability of NMP livers is limited. This retrospective, single-center study compared NMP versus static cold storage livers in first-time recipients of liver transplants through the evaluation of synthetic coagulation function as measured by thromboelastography and conventional coagulation testing. Secondarily, transfusion utilization between the 2 cohorts was reviewed. One hundred eighty-six recipients of liver transplants receiving allografts from donors after circulatory death were included in the study, of which 99 (53%) allografts were preserved in static cold storage, and 87 (47%) allografts were placed on the TransMedics Organ Care System. Study findings showed NMP livers supported with the TransMedics Organ Care System were associated with increased synthetic coagulation function and less excess fibrinolysis in the postreperfusion period compared to static cold storage livers, and that these findings were better reflected in real-time with thromboelastography monitoring versus conventional coagulation testing. Following reperfusion, there was a significant decrease in the transfusion of blood products in the NMP group compared with that in the static cold storage group. Overall, we determined that the use of intraoperative thromboelastography can provide real-time data to assess one aspect of reperfusion liver quality and viability.
Predicting Futile Recanalization After Endovascular Thrombectomy for Patients With Stroke With Large Cores: The SNAP Score
Matsukawa, Hidetoshi , Uchida, Kazutaka , Maier, Ilko , Jabbour, Pascal , Kim, Joon‐Tae , Wolfe, Stacey Q , Rai, Ansaar , Starke, Robert M. , Psychogios, Marios‐Nikos, Samaniego, Edgar A. , Grossberg, Jonathan A , Tanweer, Omar , Mascitelli, Justin, Polifka, Adam , Crosa, Roberto , Park, Min S. , Brinjikji, Waleed , Williamson, Richard , Navía, Pedro , Kan, Peter , Chowdhry, Shakeel , Ezzeldin, Mohamad , Spiotta, Alejandro M , Collaborators, for the Stroke Thrombectomy and Aneurysm Registry (STAR), Crosa, Roberto , Samaniego, Edgar A , Wolfe, Stacey Quintero , Matsukawa, Hidetoshi , Navia, Pedro , Chen, Huanwen , Elawady, Sameh Samir , Cunningham, Conor M. , Sowlat, Mohammad‐Mahdi , Jabbour, Pascal , Arthur, Adam Stephen , Yoshimura, Shinichi , Cuellar, Hugo, Alawieh, Ali , Romano, Daniele G., Mascitelli, Justin R , Fragata, Isabel , Osbun, Joshua W , Matouk, Charles , Levitt, Michael R. , Moss, Mark, Leacy, Reade De , Collaborators, for the Stroke Thrombectomy and Aneurysm Registry (STAR)

Mayo Clinic

Neurosurgery | October 11, 2024 | Volume: 96 | Issue: 5 | Pages: 1080-1088

10.1227/neu.0000000000003220 | PMID 39471074 Get It

BACKGROUND AND OBJECTIVES: We aimed to develop and validate a prediction score for futile recanalization (FR) for large vessel occlusion (LVO) presenting low Alberta Stroke Program Early Computed Tomography Score (ASPECTS) for patients who underwent endovascular thrombectomy (EVT). METHODS: Patients with anterior circulation LVO with low ASPECTS (<6) who underwent successful EVT (modified treatment in cerebral ischemia score ≥2b) from Stroke Thrombectomy and Aneurysm Registry were retrospectively analyzed. FR was defined as 90-day modified Rankin Scale (mRS) scores ≥4 despite successful EVT. Multivariable logistic regression was used to identify independent predictors of FR, and they were used to create a clinical score. The performance of the score was assessed by receiver operating characteristic curve analyses. RESULTS: Of 219 patients, 170 and 49 patients were randomly assigned to the training and validation cohort, respectively. Independent predictors of FR identified in the training cohort were used to construct the SNAP score: site of occlusion (middle cerebral artery = 0, internal carotid artery = 1), National Institutes of Health Stroke Scale score at admission (≤10 = 0, 10 to 19 = 1, ≥20 = 2), age (<75 = 0, ≥75 = 2), and prestroke mRS score (0-3). Receiver operating characteristic curve analyses of the SNAP score in the training and validation cohorts showed areas under the curve of 0.79 (95% CI 0.72-0.86) and 0.79 (95% CI 0.65-0.92) for predicting FR, respectively. A SNAP score ≥5 had a positive predictive value of 92.1% [95% CI 78.8%-97.3%] for FR. CONCLUSION: The SNAP score may be useful in predicting FR after EVT in low-ASPECTS patients with LVO. It can provide patients, family members, and physicians with reliable outcome expectations among patients with acute ischemic stroke with large infarcts.
Somatic mosaicism in schizophrenia brains reveals prenatal mutational processes
Maury, Eduardo A. , Jones, Attila , Seplyarskiy, Vladimir , Nguyen, Thanh Thanh L. , Rosenbluh, Chaggai , Bae, Taejong, Wang, Yifan , Abyzov, Alexej , Khoshkhoo, Sattar , Chahine, Yasmine, Zhao, Sijing , Venkatesh, Sanan , Root, Elise, Voloudakis, Georgios , Roussos, Panagiotis , Network‡, Brain Somatic Mosaicism, Brennand, Kristen , Reilly, Steven K. , Sunyaev, Shamil , Chess, Andrew , Bae, Taejeong , Moran, John V. , Zhou, Weichen , Zhu, Xiaowei , Bizzotto, Sara , Galor, Alon , Yang, Xiaoxu , Bae, Taejeong , Park, Peter J , Akbarian, Schahram , Brennand, Kristen , Reilly, Steven , Lee, Eunjung A , Sunyaev, Shamil R , Walsh, Christopher A , Chess, Andrew , Nguyen, Thanh Thanh L. , Abyzov, Alexej , Wang, Yifan , Voloudakis, Georgios , Maury, Eduardo A. , Jones, Attila , Seplyarskiy, Vladimir , Root, Elise , Network‡, Brain Somatic Mosaicism, Park, Peter J. , Akbarian, Schahram , Walsh, Christopher A.

Mayo Clinic

Science | October 10, 2024 | Volume: 386 | Issue: 6718 | Pages: 217-224

10.1126/science.adq1456 | PMID 39388546 Get It

Germline mutations modulate the risk of developing schizophrenia (SCZ). Much less is known about the role of mosaic somatic mutations in the context of SCZ. Deep (239×) whole-genome sequencing (WGS) of brain neurons from 61 SCZ cases and 25 controls postmortem identified mutations occurring during prenatal neurogenesis. SCZ cases showed increased somatic variants in open chromatin, with increased mosaic CpG transversions (CpG>GpG) and T>G mutations at transcription factor binding sites (TFBSs) overlapping open chromatin, a result not seen in controls. Some of these variants alter gene expression, including SCZ risk genes and genes involved in neurodevelopment. Although these mutational processes can reflect a difference in factors indirectly involved in disease, increased somatic mutations at developmental TFBSs could also potentially contribute to SCZ.
Evaluating Use of Generative Artificial Intelligence in Clinical Pathology Practice: Opportunities and the Way Forward
Jackups, Ronald , Seheult, Jansen N. , Zaydman, Mark A. , Balis, Ulysses J. , Thaker, Harshwardhan M., Rashidi, Hooman H. , Gullapalli, Rama R. , Seheult, Jansen, Seheult, Jansen N , McCaffrey, Peter

Mayo Clinic

Archives of Pathology & Laboratory Medicine | October 10, 2024 | Volume: 149 | Issue: 2 | Pages: 130-141

10.5858/arpa.2024-0208-ra | PMID 39384182 Get It

Context.— Generative artificial intelligence (GAI) technologies are likely to dramatically impact health care workflows in clinical pathology (CP). Applications in CP include education, data mining, decision support, result summaries, and patient trend assessments. Objective.— To review use cases of GAI in CP, with a particular focus on large language models. Specific examples are provided for the applications of GAI in the subspecialties of clinical chemistry, microbiology, hematopathology, and molecular diagnostics. Additionally, the review addresses potential pitfalls of GAI paradigms. Data Sources.— Current literature on GAI in health care was reviewed broadly. The use case scenarios for each CP subspecialty review common data sources generated in each subspecialty. The potential for utilization of CP data in the GAI context was subsequently assessed, focusing on issues such as future reporting paradigms, impact on quality metrics, and potential for translational research activities. Conclusions.— GAI is a powerful tool with the potential to revolutionize health care for patients and practitioners alike. However, GAI must be implemented with much caution considering various shortcomings of the technology such as biases, hallucinations, practical challenges of implementing GAI in existing CP workflows, and end-user acceptance. Human-in-the-loop models of GAI implementation have the potential to revolutionize CP by delivering deeper, meaningful insights into patient outcomes both at an individual and a population level.
Characterizing Prodrome (Premonitory Phase) in Migraine
Schwedt, Todd J. , Lipton, Richard B. , Goadsby, Peter J. , Chiang, Chia‐Chun , Klein, Brad , Hussar, Cory R. , Liu, Chengcheng , Yu, Sung Yun , Finnegan, M , Trugman, Joel M. , Lipton, R.B. , Klein, Brad C , Hussar, Cory , Finnegan, Michelle , Goadsby, Peter J , Chiang, Chia-Chun , Schwedt, Todd J

Mayo Clinic

Neurology Clinical Practice | October 8, 2024 | Volume: 15 | Issue: 1 | Pages: No page available

10.1212/cpj.0000000000200359 | PMID 39399572 Get It

Axonal damage and inflammation response are biological correlates of decline in small-world values: a cohort study in autosomal dominant Alzheimer’s disease
Vermunt, Lisa , Dicks, Ellen , Leeuw, Diederick M de , Berman, Sarah , Cash, David M. , Chhatwal, Jasmeer P. , Cruchaga, Carlos , Day, Gregory S. , Ewers, Michael , Farlow, Martin R. , Fox, Nick C. , Ghetti, Bernardino , Graff‐Radford, Neill R., Hassenstab, Jason , Laske, Christoph , Xiong, Chengjie , Masters, Colin L. , Mori, Hiroshi , Morris, John C. , Perrin, Richard J. , Preische, Oliver, Xiong, Chengjie , Fagan, Anne M. , de Leeuw, Diederick M , Cash, David M , Chhatwal, Jasmeer , Cruchaga, Carlos , Ewers, Michael , Kuhle, Jens , Masters, Colin L , Morris, John C , Teunissen, Charlotte E , Bateman, Randall J , Gordon, Brian A , Tijms, Betty M , Day, Gregory S , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Ghetti, Bernardino F , Berman, Sarah , Sutphen, Courtney L. , Allegri, Ricardo , Graff‐Radford, Neill R. , Jucker, Mathias , Karch, Celeste M. , Kühle, Jens , McDade, Eric , Schofield, Peter R. , Suárez‐Calvet, Marc , Xiong, Chengjie , Scheltens, Philip , Teunissen, Charlotte E. , Visser, Pieter Jelle , Bateman, Randall J. , Benzinger, Tammie L.S. , Gordon, Brian A. , Tijms, Betty M.

Mayo Clinic

Brain Communications | October 7, 2024 | Volume: 6 | Issue: 5 | Pages: No page available

10.1093/braincomms/fcae357 | PMID 39440304 Get It

Abstract The grey matter of the brain develops and declines in coordinated patterns during the lifespan. Such covariation patterns of grey matter structure can be quantified as grey matter networks, which can be measured with magnetic resonance imaging. In Alzheimer’s disease, the global organization of grey matter networks becomes more random, which is captured by a decline in the small-world coefficient. Such decline in the small-world value has been robustly associated with cognitive decline across clinical stages of Alzheimer’s disease. The biological mechanisms causing this decline in small-world values remain unknown. Cerebrospinal fluid (CSF) protein biomarkers are available for studying diverse pathological mechanisms in humans and can provide insight into decline. We investigated the relationships between 10 CSF proteins and small-world coefficient in mutation carriers (N = 219) and non-carriers (N = 136) of the Dominantly Inherited Alzheimer Network Observational study. Abnormalities in Amyloid beta, Tau, synaptic (Synaptosome associated protein-25, Neurogranin) and neuronal calcium-sensor protein (Visinin-like protein-1) preceded loss of small-world coefficient by several years, while increased levels in CSF markers for inflammation (Chitinase-3-like protein 1) and axonal injury (Neurofilament light) co-occurred with decreasing small-world values. This suggests that axonal loss and inflammation play a role in structural grey matter network changes.
Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial
Khan, Aliya , Rubin, Mishaela R. , Vokes, Tamara , Shoback, Dolores , Palermo, Andrea , Abbott, Lisa G, Hofbauer, Lorenz C. , Kohlmeier, Lynn, Pihl, Susanne, An, Xuebei, Lai, Bryant, Ukena, Jenny, Shu, Aimee D , Shoback, Dolores M , Gagnon, Claudia , Palermo, Andrea , Cetani, Filomena , Shu, Aimee D , Rejnmark, Lars , Hofbauer, Lorenz C , Clarke, B.L. , Schwarz, Peter , Smith, Alden Raymond , Sibley, Christopher T. , Rejnmark, Lars

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | October 7, 2024 | Volume: 110 | Issue: 4 | Pages: 951-960

10.1210/clinem/dgae693 | PMID 39376010 Get It

Abstract Context Conventional therapy for hypoparathyroidism aims to alleviate symptoms of hypocalcemia but does not address insufficient parathyroid hormone (PTH) levels. Objective Assess the long-term efficacy and safety of TransCon PTH (palopegteriparatide) for hypoparathyroidism. Design Phase 3 trial with a 26-week, double-blind, placebo-controlled period followed by a 156-week, open-label extension (OLE). Setting Twenty-one sites across North America and Europe. Participants A total of 82 adults with hypoparathyroidism were randomized and received study drug and 78 completed week 52. Intervention(s) All OLE participants received TransCon PTH administered once daily. Main Outcome Measure(s) Multicomponent efficacy endpoint: proportion of participants at week 52 who achieved normal serum calcium (8.3-10.6 mg/dL) and independence from conventional therapy (≤600 mg/day of elemental calcium and no active vitamin D). Other efficacy endpoints included patient-reported outcomes and bone mineral density. Safety was assessed by 24-hour urine calcium and treatment-emergent adverse events. Results At week 52, 81% (63/78) met the multicomponent efficacy endpoint, 95% (74/78) achieved independence from conventional therapy, and none required active vitamin D. Patient-reported outcomes showed sustained improvements in quality of life, physical functioning, and well-being. Mean bone mineral density Z-scores decreased toward age- and sex-matched norms from baseline to week 52. Mean (SD) 24-hour urine calcium excretion decreased from 376 (168) mg/day at baseline to 195 (114) mg/day at week 52. Most treatment-emergent adverse events were mild or moderate and none led to trial discontinuation during the OLE. Conclusion At week 52 of the PaTHway trial, TransCon PTH showed sustained efficacy, safety, and tolerability in adults with hypoparathyroidism.
9295 Characteristics Of Adults with Autosomal Dominant Hypocalcemia Type 1 (ADH1) Enrolled In The CLARIFY Disease Monitoring Study
Harmatz, Paul , Warren, Mark , Ma, Nina, Khan, Aliya , Lemoine, Sandrine, Mantovani, Giovanna, Wasserman, Halley , Barbosa, Ana Paula , Cardot-Bauters, Catherine, Roberts, Mary Scott , Mathew, Arun, Adler, Scott, Zillikens, Maria Carola, Ing, Steven , Mora, Stefano , Imel, Erik Allen , Tebben, Peter J. , Palermo, Andrea, Decallonne, Brigitte , Lemoine, Sandrine , Linglart, Agnès , Barbosa, Ana Paula, Clifton-Bligh, Roderick , Rejnmark, Lars

Mayo Clinic

Journal of the Endocrine Society | October 5, 2024 | Volume: 8 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvae163.383 Get It

Abstract Disclosure: S.W. Ing: Advisory Board Member; Self; Ultragenyx, Amolyt. Grant Recipient; Self; Alexion Pharmaceuticals, Inc.. Research Investigator; Self; BridgeBio Pharma, Takeda, Amolyt, Radius Health, Inc, Ultragenyx. P. Harmatz: Research Investigator; Self; BridgeBio Pharma. S. Mora: Research Investigator; Self; BridgeBio Pharma. E.A. Imel: Research Investigator; Self; BridgeBio Pharma. P.J. Tebben: Research Investigator; Self; BridgeBio Pharma. M.L. Warren: Research Investigator; Self; BridgeBio Pharma, Ascendis, Amolyt. Speaker; Self; Ascendis. N. Ma: Research Investigator; Self; Calcilytix Therapeutics, Ultragenyx, Inozyme. Other; Self; Up To Date. A.A. Khan: Research Investigator; Self; BridgeBio Pharma, Ascendis. A. Palermo: Research Investigator; Self; BridgeBio Pharma. B. Decallonne: Research Investigator; Self; BridgeBio Pharma. S. Lemoine: Research Investigator; Self; BridgeBio Pharma, Kyowa Kirin. G. Mantovani: Research Investigator; Self; BridgeBio Pharma. A. Linglart: Consulting Fee; Self; Alexion, Novo Nordisk, Merck, Pfizer, Inc.. Research Investigator; Self; BridgeBio Pharma, Kyowa Kirin. H. Wasserman: Research Investigator; Self; BridgeBio Pharma. A.P. Barbosa: Research Investigator; Self; BridgeBio Pharma. C. Cardot-bauters: Research Investigator; Self; BridgeBio Pharma. M. Roberts: Employee; Self; BridgeBio Pharma. A. Mathew: Employee; Self; BridgeBio Pharma. S. Adler: Employee; Self; BridgeBio Pharma. M.C. Zillikens: Research Investigator; Self; BridgeBio Pharma. R.J. Clifton-Bligh: Consulting Fee; Self; Ipsen, Kyowa Kirin, Amgen Inc, Eisai. Research Investigator; Self; BridgeBio Pharma. L. Rejnmark: Research Investigator; Self; BridgeBio Pharma, Ascendis, Amolyt, Takeda, Kyowa Kirin. Autosomal dominant hypocalcemia type 1 (ADH1), caused by gain-of-function calcium-sensing receptor gene (CASR) variants, is characterized by low parathyroid hormone (PTH) concentrations, hypocalcemia, hypercalciuria, hyperphosphatemia and hypomagnesemia. While a rare disease, ADH1 is one of the more frequently identified causes of genetic hypoparathyroidism. Conventional therapy includes calcium (Ca) and/or active vitamin D, but this regimen incompletely corrects the hypocalcemia and is associated with persistent hypercalciuria, which may result in renal complications including nephrocalcinosis (NC), nephrolithiasis (NL), and chronic kidney disease (CKD). The CLARIFY disease monitoring study [NCT05227287] is a global, multicenter, longitudinal study to understand disease burden, management, and progression in children and adults with ADH1 over a 5-year period. Here we report data on the characteristics of adult participants at study entry. As of November 2023, 45 adults (≥18 years) with ADH1 were enrolled, with a mean±SD age of 42.1±16.5 years (range 18-80). The mean±SD age of a hypocalcemia diagnosis was 19.1±19.1 years, while the mean±SD age for a diagnosis of ADH1 was 28.2±20.6 years. As reported on medical history, in decreasing order of prevalence, 36% (16) had NC, 22% (10) had intracranial calcifications, 11% (5) had history of seizures, 11% (5) had CKD, 9% (4) had cataracts, 7% (3) had NL, and 4% (2) had undergone renal transplant. Treatment data were available for 43 participants and included the following: 74% (32) Ca and active vitamin D, 9% (4) Ca alone, 9% (4) active vitamin D alone, 37% (16) magnesium, 33% (14) thiazide diuretics, 26% (11) potassium, 7% (3) phosphate binder, 7% (3) PTH, and 5% (2) no treatment. Mean±SD fasting values collected prior to conventional therapy dose are presented. PTH concentrations (10.1±8.2 pg/mL [nl 15-65]) and albumin-corrected calcium ([cCa]=7.5±1.0 mg/dL [nl 8.5-10.5]) were low. Despite the low mean cCa, the mean 24-hr urine calcium was elevated (268±183 mg/d, [nl &lt;250 women, &lt;300 men]). Blood phosphate was 4.8±0.8 mg/dL [nl 2.5-4.8] while blood magnesium was 1.8±0.2 mg/dL [nl 1.8-2.4]. 25-OH vitamin D was 35.0±13.5 ng/mL [nl 30-80]. Renal function as assessed by CKD-EPIcr_R showed eGFR of 86±23 mL/min/1.73m² (range 36-123). This study represents the largest cohort of adults with ADH1 described to date. These data highlight variability in therapeutic approaches in a real-world setting with some participants receiving up to 6 different medications/supplements. Despite being followed in expert centers, and treated with available therapies, patients on average have low cCa with relatively high 24-hr urine calcium excretion. The CLARIFY study provides an opportunity to better understand the progression and burden of disease in participants with ADH1. Presentation: 6/3/2024
8669 Characteristics Of Adults with Autosomal Dominant Hypocalcemia Type 1 (ADH1) Enrolled In The CLARIFY Disease Monitoring Study
Harmatz, Paul , Warren, Mark , Ma, Ning , Khan, Aliya , Mantovani, Giovanna, Barbosa, Arsénio, Cardot‐Bauters, C., Roberts, Mary Scott , Adler, Scott, Ing, Steven , Mora, Stefano , Imel, Erik Allen , Tebben, Peter J. , Ma, N, Palermo, A, Decallonne, Brigitte , Lemoine, Sandrine , Linglart, Agnès , Wasserman, H, Barbosa, A P, Mathew, A, Zillikens, M. Carola , Clifton-Bligh, Roderick , Rejnmark, Lars

Mayo Clinic

Journal of the Endocrine Society | October 5, 2024 | Volume: 8 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvae163.384 Get It

Abstract Disclosure: S.W. Ing: Research Investigator; Self; BridgeBio Pharma. P. Harmatz: Research Investigator; Self; BridgeBio Pharma. S. Mora: Research Investigator; Self; BridgeBio Pharma. E.A. Imel: Research Investigator; Self; BridgeBio Pharma. P.J. Tebben: Research Investigator; Self; BridgeBio Pharma. M.L. Warren: Research Investigator; Self; BridgeBio Pharma, Ascendis, Amolyt. Speaker; Self; Ascendis. N. Ma: Research Investigator; Self; Calcilytix Therapeutics, Ultragenyx, Inozyme. Other; Self; Up To Date. A.A. Khan: Research Investigator; Self; BridgeBio Pharma, Ascendis. A. Palermo: Research Investigator; Self; BridgeBio Pharma. B. Decallonne: Research Investigator; Self; BridgeBio Pharma. S. Lemoine: Research Investigator; Self; BridgeBio Pharma, Kyowa Kirin. G. Mantovani: Research Investigator; Self; BridgeBio Pharma. A. Linglart: Consulting Fee; Self; Alexion, Novo Nordisk, Merck, Pfizer, Inc.. Research Investigator; Self; BridgeBio Pharma, Kyowa Kirin. H. Wasserman: Research Investigator; Self; BridgeBio Pharma. A.P. Barbosa: Research Investigator; Self; BridgeBio Pharma. C. Cardot-bauters: Research Investigator; Self; BridgeBio Pharma. M. Roberts: Employee; Self; BridgeBio Pharma. A. Mathew: Employee; Self; BridgeBio Pharma. S. Adler: Employee; Self; BridgeBio Pharma. M.C. Zillikens: Research Investigator; Self; BridgeBio Pharma. R.J. Clifton-Bligh: Consulting Fee; Self; Ipsen, Kyowa Kirin, Amgen Inc, Eisai. Research Investigator; Self; BridgeBio Pharma. L. Rejnmark: Research Investigator; Self; BridgeBio Pharma, Ascendis, Amolyt, Takeda, Kyowa Kirin. Autosomal dominant hypocalcemia type 1 (ADH1), caused by gain-of-function calcium-sensing receptor gene (CASR) variants, is characterized by low parathyroid hormone (PTH) concentrations, hypocalcemia, hypercalciuria, hyperphosphatemia and hypomagnesemia. While a rare disease, ADH1 is one of the more frequently identified causes of genetic hypoparathyroidism. Conventional therapy includes calcium (Ca) and/or active vitamin D, but this regimen incompletely corrects the hypocalcemia and is associated with persistent hypercalciuria, which may result in renal complications including nephrocalcinosis (NC), nephrolithiasis (NL), and chronic kidney disease (CKD). The CLARIFY disease monitoring study [NCT05227287] is a global, multicenter, longitudinal study to understand disease burden, management, and progression in children and adults with ADH1 over a 5-year period. Here we report data on the characteristics of adult participants at study entry. As of November 2023, 45 adults (≥18 years) with ADH1 were enrolled, with a mean±SD age of 42.1±16.5 years (range 18-80). The mean±SD age of a hypocalcemia diagnosis was 19.1±19.1 years, while the mean±SD age for a diagnosis of ADH1 was 28.2±20.6 years. As reported on medical history, in decreasing order of prevalence, 36% (16) had NC, 22% (10) had intracranial calcifications, 11% (5) had history of seizures, 11% (5) had CKD, 9% (4) had cataracts, 7% (3) had NL, and 4% (2) had undergone renal transplant. Treatment data were available for 43 participants and included the following: 74% (32) Ca and active vitamin D, 9% (4) Ca alone, 9% (4) active vitamin D alone, 37% (16) magnesium, 33% (14) thiazide diuretics, 26% (11) potassium, 7% (3) phosphate binder, 7% (3) PTH, and 5% (2) no treatment. Mean±SD fasting values collected prior to conventional therapy dose are presented. PTH concentrations (10.1±8.2 pg/mL [nl 15-65]) and albumin-corrected calcium ([cCa]=7.5±1.0 mg/dL [nl 8.5-10.5]) were low. Despite the low mean cCa, the mean 24-hr urine calcium was elevated (268±183 mg/d, [nl &lt;250 women, &lt;300 men]). Blood phosphate was 4.8±0.8 mg/dL [nl 2.5-4.8] while blood magnesium was 1.8±0.2 mg/dL [nl 1.8-2.4]. 25-OH vitamin D was 35.0±13.5 ng/mL [nl 30-80]. Renal function as assessed by CKD-EPIcr_R showed eGFR of 86±23 mL/min/1.73m² (range 36-123). This study represents the largest cohort of adults with ADH1 described to date. These data highlight variability in therapeutic approaches in a real-world setting with some participants receiving up to 6 different medications/supplements. Despite being followed in expert centers, and treated with available therapies, patients on average have low cCa with relatively high 24-hr urine calcium excretion. The CLARIFY study provides an opportunity to better understand the progression and burden of disease in participants with ADH1. Presentation: 6/3/2024